Histone Deacetylase Inhibitor Drug Class List

Drugs in Drug Class: Histone Deacetylase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y	Y
Acrotech Biopharma	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014		RX	Yes	Yes			Y
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes			Y
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes			Y	Y
Italfarmaco Spa	DUVYZAT	givinostat hydrochloride	SUSPENSION;ORAL	217865-001	Mar 21, 2024		RX	Yes	Yes

Histone Deacetylase Inhibitor (HDACi) Market Dynamics and Patent Landscape

Last updated: April 25, 2026

Where is the HDAC inhibitor market growing, and what drives demand?

HDAC inhibitors (HDACi) are a core oncology modality centered on transcriptional regulation via histone acetylation and broader epigenetic effects. Demand is shaped by (1) the adoption of established monotherapies and combination regimens in hematologic malignancies, (2) the clinical trajectory of newer HDACi across earlier lines of therapy, and (3) competitive differentiation based on selectivity (class I/II vs broader), dosing schedules, and tolerability.

Key market dynamics

• Oncology-led use: The commercial base of HDACi is primarily oncology, with the highest utilization in multiple myeloma and other hematologic cancers. HDACi value increases when used in combinations that improve response depth or duration.
• Combination dependency: Most late-stage HDACi value propositions are tied to combination regimens with standard backbone therapies (for example, proteasome inhibitors and immunomodulators in myeloma). This matters for pricing power and pull-through, because payer coverage and treatment pathways often hinge on combination evidence.
• Safety and dosing constraints: HDACi are limited by class-related toxicities (fatigue, GI effects, thrombocytopenia and anemia, infections). Clinical differentiation often comes from improved tolerability that enables sustained dosing or combination intensity.
• Regulatory and labeling specificity: HDACi uptake tends to track label expansion into additional subtypes, lines, or combination partners. Where labels are narrow, utilization concentrates around the most compelling trial-driven settings.

Commercial reference points (selected HDAC inhibitors)

The most visible commercial HDAC inhibitors illustrate how the market consolidates around products with (a) durable label coverage and (b) combination usage patterns.

Drug (HDACi)	Core positioning	Commercial dynamic
Vorinostat (SAHA)	Oncology; established	Differentiated by initial approvals and durable adoption in selected settings
Romidepsin (depsipeptide)	Oncology; established	Competitive pressure from newer regimens; label-driven use persists
Panobinostat	Oncology; multiple myeloma	Label anchoring in myeloma combinations supports continued demand
Belinostat	Oncology; hematologic malignancies	Adoption tied to specific label-defined indications
Entinostat	HDACi; development stage historically focused on oncology	Market impact shaped by trial outcomes vs SOC in combination settings

(Drug-level sales and payer economics vary by geography and year; the patent and competitive sections below explain why exclusivity and lifecycle strategy largely determine net market capture.)

---

What does the HDAC inhibitor patent landscape look like (by exclusivity type and typical claim focus)?

HDAC inhibitors sit in a crowded IP field. The landscape generally clusters into four patent layers:

1. Core compound patents (small-molecule structure, chirality, polymorphs where supported).
2. Formulation and manufacturing patents (solid state, salts, amorphous forms, controlled release; process patents for intermediate synthesis).
3. Method-of-use patents (treatment methods, lines of therapy, patient subgroups, dosing regimens, biomarkers).
4. Combination patents (HDACi + other anticancer agents, often specifying sequences, dosage ranges, and regimen schedules).

Typical claim themes in HDACi

• Combination regimens: A high share of enforceable value comes from combination claim drafting that ties dosing schedules to a partner agent (e.g., HDACi at specific mg levels on defined cycles with a standard-of-care partner).
• Biomarkers and subpopulations: Patents increasingly rely on response biomarkers or genetic/epigenetic markers to justify narrower, more enforceable clinical claim scope.
• Next-generation chemical matter: Many filings target selectivity shifts (class I vs broad HDAC inhibition), altered linker architectures, or improved pharmacokinetics.
• Pharmaceutical compositions: Formulation patents often extend effective exclusivity through solid form IP even when compound claims expire.

How exclusivity interacts with the competitive cycle

• When compound exclusivity wanes, method-of-use and combination patents often sustain market leverage by shifting the legal fight from “what the molecule is” to “how it is used.”
• Where multiple competitors chase similar regimens, patent estates become fragmented, raising the importance of freedom-to-operate (FTO) mapping across not just compound structures but also regimen claims and manufacturing routes.

---

Which HDAC inhibitors anchor the patent fight (and why)?

The market’s legal and commercial gravity concentrates around the established products and their lifecycle estates. These products have historically used layered IP to extend market access.

Vorinostat (SAHA)

Vorinostat is an early entry point for HDACi. The patent landscape tends to include:

• Core chemical matter coverage (historically from earlier filings).
• Lifecycle coverage via formulations and specific use regimens.

Implication for FTO and generic entry: As core chemical matter approaches expiry, remaining leverage often comes from method-of-use and formulation claims tied to specific dosing and patient selection.

Panobinostat

Panobinostat’s major commercial demand has been linked to multiple myeloma combination regimens, driving a patent estate focused on:

• Combination therapy regimens.
• Dosing schedules and cycles consistent with clinical protocols.

Implication: Combination claims often become the practical barrier to substitution, particularly if the branded label aligns tightly with the patented regimen.

Romidepsin

Romidepsin’s IP picture generally emphasizes:

• Method-of-use claims in oncologic settings.
• Lifecycle additions via formulation approaches.

Belinostat

Belinostat’s patent estate typically includes:

• Use claims tied to defined hematologic indications.
• Formulation and dosing regimens.

Next-generation HDACi (broader selectivity and improved tolerability)

New entrants and challengers tend to file around:

• Selective HDAC inhibition profiles.
• Novel dosing schedules aimed at tolerability and adherence.
• Combination packages designed to fit into evolving standard-of-care lines.

---

How do regulatory exclusivity structures shape HDACi market access?

Patent estates in HDACi are reinforced by regulatory exclusivity regimes and labeling strategies. In the US, FDA exclusivity typically includes:

• New Chemical Entity (NCE) exclusivity (if eligible).
• Orphan Drug exclusivity when granted.
• 5-year exclusivity for certain non-patent exclusivities (context-dependent).
• 3-year exclusivity for changes requiring additional clinical data.

In practice, HDACi companies use:

• Label expansion to extend commercial runway.
• Lifecycle patents to extend effective exclusivity past earliest composition-of-matter expiry.
• Exclusivity stacking where orphan indications exist.

These mechanisms affect timing for generic or biosimilar-like competitive entry (for small molecules, generics) and determine when payers and formularies are willing to switch.

---

Where is IP most likely to be enforceable: compound vs regimen vs formulation?

Across HDACi, enforceability often concentrates in combination and regimen claims because they map directly to clinical practice and are harder to “design around” without altering the therapeutic protocol.

Design-around reality

• Compound patents are design-around barriers if the generic must copy the structure to be bioequivalent. However, many competitors route around by using different chemical matter.
• Method-of-use patents constrain substitution if the generic company’s label and real-world prescribing overlaps with the patented method. Practical enforceability increases where claims are drafted to cover standard dosing schedules reflected in the label.
• Formulation and manufacturing patents matter when the generic relies on different solid forms, polymorphs, or process steps. Even when the active moiety is generic, a branded formulation may be protected.

---

What competitive patterns define the HDACi landscape today?

1) Product-by-regimen positioning

Brand value frequently attaches to the regimen, not just to the molecule. This pushes patent drafting toward:

• Specific HDACi dosing ranges.
• Cycle definitions (day-by-day or week-by-week administration).
• Combination partner dosing and sequencing.

2) Increasing specificity in claim drafting

As generic challengers become more sophisticated, claim drafting often includes narrower patient populations or specific therapeutic goals:

• Biomarker-positive groups.
• Disease stage or line-of-therapy restrictions.
• Response-based endpoints tied to dosing schedule.

3) Lifecycle management under tightening competition

HDACi companies increasingly invest in:

• Solid-state IP (amorphous vs crystalline forms where supported).
• Extended-release or modified-release compositions.
• Process patents aimed at intermediate synthesis yields and impurity profiles.

---

How do key global IP policy frameworks affect HDACi patent strategies?

Patent strategy for HDACi is shaped by how jurisdictions treat:

• Inventive step and novelty of new chemical entities vs incremental modifications.
• Enablement and written description for method-of-use and biomarker claims.
• Claim breadth in combination regimens.

The market outcome is often a function of whether the claim set survives across multiple litigations and exam standards rather than whether the company owns a single strong composition-of-matter patent.

---

Key takeaways

• Demand is regimen-led: HDACi uptake correlates with combination evidence, not standalone activity. Patent value maps to patented regimen claim scope.
• Patent estates are layered: market leverage comes from combinations, method-of-use, and formulation/manufacturing patents that extend beyond core compound expiry.
• Design-around is protocol-sensitive: the practical obstacle for generic entry is often a patented method or formulation route that overlaps with labeled clinical practice.
• Exclusivity stacking and label expansion matter: regulatory exclusivities and label scope influence timing and payer willingness to switch.

---

FAQs

1) Which HDACi claims typically block generic entry the longest?

Combination regimen and method-of-use claims that align with branded labeling and standard clinical schedules.

2) Are formulation patents a meaningful barrier in HDACi?

Yes, particularly for protected solid-state forms and manufacturing processes that require different formulation routes or solid form generation.

3) What claim areas create the highest litigation risk?

Broad method-of-use claims and combination regimen claims that overlap with real-world prescribing and are difficult to “switch off” without changing the therapeutic protocol.

4) How does biomarker-based claiming change the landscape?

It narrows the claim scope but can improve enforceability by tying treatment to defined patient subgroups and asserted biological mechanisms.

5) What is the commercial signal of patent estate strength for HDACi?

Sustained label coverage with ongoing combination inclusion plus continued filing activity in regimen, formulation, and process families.

---

References

[1] U.S. Patent and Trademark Office. (n.d.). Patent term adjustments and extensions. https://www.uspto.gov
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA drug approvals and labeling information. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] European Patent Office. (n.d.). Guidelines for examination in the EPO. https://www.epo.org/law-practice/legal-texts/guidelines.html
[4] World Health Organization. (n.d.). WHO guidelines and medicine regulatory frameworks. https://www.who.int
[5] FDA. (2024). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/